EGFR and non-small cell lung carcinoma: Among the different EGFR inhibitors currently approved in oncology, gefitinib is a selective EGFR tyrosine kinase inhibitor (EGFR-TKI) indicated for the treatment of patients with advanced or metastatic non-small-cell lung cancer (NSCLC) harbouring activating mutations of EGFR8.